Compare Aptiv PLC (APTV) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aptiv PLC vs Zoetis Inc — how do they compare? Aptiv PLC trades at $60.08 (market cap $12.82B), while Zoetis Inc trades at $75.97 (market cap $31.68B). The key difference: Zoetis Inc is far larger — about 2.5× Aptiv PLC's market cap, and Zoetis Inc pays a 2.81% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | ZTS | |
|---|---|---|
Market Cap | $12.82B | $31.68B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $156.76 |
52-Week Low | $52.57 | $71.91 |
Enterprise Value | $19.53B | $38.97B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
Zoetis (ZTS) trades at $75.56, up 0.64% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 28.03% net margins and 67.75% ROE, supported by consistent revenue growth to $9.47B in 2025. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with a $101.43 price target. Legal developments include multiple securities class action notices with July 27, 2026 deadlines.
ZTS presents a mixed outlook with strong fundamental performance offset by technical weakness and legal overhangs. The stock trades at attractive valuations (P/E 12.39) with significant upside to analyst targets, but investors face near-term volatility from the class action proceedings and recent earnings miss. Long-term growth prospects remain solid given the company's market leadership in animal health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
